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Beta amyloid aggregates induce sensitised
TLR4 signalling causing long-term potentiation
deficit and rat neuronal cell death
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The molecular events causing memory loss and neuronal cell death in Alzheimer’s disease
(AD) over time are still unknown. Here we found that picomolar concentrations of soluble
oligomers of synthetic beta amyloid (Aβ42) aggregates incubated with BV2 cells or rat
astrocytes caused a sensitised response of Toll-like receptor 4 (TLR4) with time, leading to
increased production of TNF-α. Aβ aggregates caused long term potentiation (LTP) deficit in
hippocampal slices and predominantly neuronal cell death in co-cultures of astrocytes and
neurons, which was blocked by TLR4 antagonists. Soluble Aβ aggregates cause LTP deficit
and neuronal death via an autocrine/paracrine mechanism due to TLR4 signalling. These
findings suggest that the TLR4-mediated inflammatory response may be a key pathophy-
siological process in AD.
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Memory loss is a very common symptom of Alzheimer’sdisease (AD), however the molecular basis by whichmemory loss occurs is not understood1. This means it is
currently challenging to develop treatments for AD. A synaptic
correlate of memory is long-term potentiation (LTP). LTP is
widely considered one of the major cellular mechanisms that
underlies learning and memory. It has been found that soluble
beta-amyloid (Aβ) aggregates from a variety of sources including
soaked brain2, brain homogenate, concentrated CSF and syn-
thetic aggregates3,4 can cause LTP deficit in brain slices. Sig-
nificant efforts have been made to identify the nature of the
aggregates that affect LTP deficit, so they can be targeted for
potential therapy. Antibodies that bind the N-terminus of Aβ4 4,
knock-out of PrP or the use of PrP antibodies5 have all been
shown to be effective in preventing aggregate-induced LTP defi-
cit. These results show that soluble Aβ aggregates initiate LTP
deficit, but the mechanism by which this occurs and whether it is
a result of the direct interaction of aggregates with synapses or
occurs by a different mechanism has not been established to date.
In vivo, Aβ can be post-translationally modified and interact with
other proteins present, so that the aggregates present are het-
erogeneous in both size and composition. In contrast, synthetic
aggregates made by aggregating Aβ42 in the test-tube are only
heterogeneous in size not composition and still capable of causing
LTP deficit4. In most experiments the aggregate concentration is
not measured but only the total Aβ monomer concentration is
known. This means that while it has been observed that brain-
derived aggregates are more effective at causing LTP deficit than
synthetic Aβ aggregates this could simply occur because the
concentration of aggregates is higher in the preparations used.
It is not possible to determine which type of aggregate is
more effective at causing LTP without knowing the aggregate
concentration.
Aβ aggregates can trigger the production of a number of
proinflammatory cytokines, including TNF-α, from astrocytes and
microglia6,7, and the media from conditioned astrocytes is toxic to
neurons8 suggesting that neuronal cell death can occur via an
inflammatory mechanism. One of the routes that pro-
inflammatory cytokines are produced occurs via Toll-like recep-
tors, pattern recognition molecules that recognize damaged
molecules, particularly TLR2 and TLR49,10. Our recent work
shows that synthetic Aβ aggregates exist in a range of different
sizes and structures with the longer protofibrils being the
inflammatory species and signal via TLR411. There is a crystal
structure of TLR3, which is in the same family as TLR4, bound to
an RNA dimer which is about 2 nm in diameter12. TLR3 signalling
occurs when the RNA dimer is longer than 15 nm13. This suggests
that long protofibrillar Aβ aggregates, which have a comparable
diameter, initiate TLR4 signalling by forming a similar structure
with a TLR4 dimers bound along the protofibril, providing a
plausible explanation of both why they are the inflammatory
species and how they initiate TLR4 signalling. However, to date,
this experiment and many other experiments on aggregate
induced inflammation have been performed at high aggregate
concentrations in short time periods, typically 24 h. Therefore,
there are important questions about the relevance of the results
obtained at these high aggregate doses to AD. In particular, it is
not clear how the response is altered at more relevant physiolo-
gical concentrations of aggregates applied over longer times or if
TLR4 signalling occurs at all. To address this issue, we first
explored the response of BV2 microglial to extended doses of low
concentrations of soluble aggregates, close to physiological levels,
finding that this leads to sensitized response to these aggregates
due to TLR4 signalling. We then explored if this aggregate-
induced inflammatory response could lead to LTP deficit and
neuronal cell death, cellular correlates of the symptoms associated
with the development of AD, by performing experiments in the
presence and absence of TLR4 antagonists.
Results
Pro-inflammatory response of macrophages to beta -amyloid.
Experiments were firstly performed using synthetic oligomers of
Aβ1-42, made by aggregating monomer and characterised by
single molecule fluorescence, allowing us to estimate the soluble
aggregate concentration14,15, and hence be able to perform
reproducible experiments. These soluble aggregates, oligomers,
are predominantly trimers and tetramers although they range in
size from dimer to 20mers14 and are stable once formed allowing
solutions of different initial aggregate concentrations to be made
by serial dilution. This enables us to work at close to physiological
concentrations of Aβ aggregates. Our initial experiments con-
firmed previous results that Aβ oligomers but not fibril or
monomer lead to the production of TNF-α and IL-β in a BV2
microglial cell line and astrocytes in 24 h (Figs. 1 and 2). The
synthetic Aβ monomer produced no TNF-α which confirmed
that it contained no endotoxin contaminants. Using TLR4 and
Myd88 knock-out cell lines we then showed that signalling was
predominantly mediated by TLR4 and Myd88 (Fig. 1). We then
performed experiments at lower aggregate concentrations
for several days, close to the physiological concentration of
1–10 pM16. Control experiments showed that there was no sig-
nificant change in the number of aggregates during the 24 hours’
incubation with cells, before buffer exchange, for total monomer
Fig. 1 Pro-inflammatory response of TLR4, MyD88 or TLR2 knockout macrophages to Abeta42(Aβ) oligomers and fibrils. Cells (WT: wild type,
MyD88−/−: MyD88 knockout, TLR4−/−: TLR4 knock out and TLR2−/−: TLR2 knockout) were stimulated with Aβ Fibrils (0.1–400 nM) and Aβ oligomers
together with monomer (total monomer concentration 0.02–80 μM) for 24 h. The levels of the pro-inflammatory mediators TNF-α and IL-1β were
measured. a TNF-α production remained unchanged at all concentrations with the addition of Fibrils (n= 5, ±sem). b TNF-α production significantly
increases with increasing oligomer concentrations in all except the TLR4 knockout cells (n= 5, ±sem). c IL-1β levels production significantly increases
with increasing oligomer concentrations in all except the TLR4 knockout cells (n= 5, mean ± sem).
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concentrations below about 10 nM which is estimated to contain
350 pM soluble aggregates (Supplementary Fig. 1). Above 10 nM
total monomer there is formation of additional aggregates, so the
oligomer dose increases with time. There is also no significant cell
death for total monomer concentrations below 40 nM (Supple-
mentary Fig. 2). We found that both BV2 microglial cell line and
astrocytes showed a sensitized response with time and this was
significant at oligomer concentrations down to 10 pM (Fig. 2), but
there was no measurable response in TLR4 and Myd88 knockout
cell lines (Supplementary Fig. 3). The Aβ aggregate-induced
TLR4 signalling can be effectively blocked by the TLR4 antago-
nists RSLA and TAK-242 (Fig. 2).
LTP deficit experiments. Next, we tested whether the Aβ-
mediated LTP deficit involved TLR4 signalling. Using rat hip-
pocampal slices Aβ aggregates were pre-incubated for a few hours
before measurement of LTP. At 500 nM total Aβ monomer
(~15 nM oligomers), 100 Hz electric stimulation-induced LTP in
control slices (156.3 ± 5.3%, n= 6), this was inhibited in slices
treated with Aβ oligomers (110.9 ± 3.1%, n= 6; Control vs. Aβ,
p= 0.0000228). Treatment with RSLA prevented the Aβ-
mediated inhibition of LTP (146.7 ± 3.2%, n= 6; RSLA with Aβ
vs. Aβ, p= 0.0000112; control vs. RSLA with Aβ, p= 0.155;
Fig. 3a). However, TAK-242 (100 ng–1 μg/ml) did not prevent
Aβ-mediated inhibition of LTP (TAK-242 with Aβ (111.6 ± 8.2%,
n= 6); TAK-242 with Aβ vs. Aβ, p= 0.410; Control vs. TAK-242
with Aβ, p= 0.00414; Fig. 3b). TAK-242 and RSLA had no effect
on the magnitude of LTP induction compared with control
(control: 155.9 ± 5.7%, n= 7; Tak-242: 153.2 ± 6.5%, n= 6; RSLA:
160.1 ± 8.1%, n= 6; Fig. 3c). RSLA directly blocks the TLR4-
binding site17 while TAK-242 binds an intracellular domain of
TLR417,18 and hence may less effectively reach its binding site in
the brain slice. An Elisa assay was performed which showed
increased production of TNF-α in the hippocampus on addition
of Aβ aggregates (Supplementary Fig. 4). These results together
show that Aβ aggregate-induced LTP deficit can be reduced by
blocking TLR4 signalling.
Neuronal cell death. The next set of experiments were designed
to determine whether neuronal cell death was mediated by the
direct action of aggregates acting on neurons and how much was
mediated by cytokines produced by TLR4 signalling by a para-
crine/autocrine mechanism. Rat neurons (E16–17), enriched
astrocytes (purchased from Science Cell) and a co-culture of
astrocytes and neurons (P2–P4) were exposed to 1 μM of aggre-
gated Aβ containing ~15 nM oligomers in the absence or pre-
sence of specific inhibitors of TLR4 signalling, RSLA and TAK-
242 (Fig. 4 and Supplementary Fig. 5). Addition of aggregated Aβ
to enriched astrocyte cultures induced astrocytic cell death that
was prevented by TLR4 antagonists. Addition of aggregated Aβ to
enriched neuronal cultures induced neuronal cell death, and this
was not significantly prevented by both TLR4 antagonists.
Notably, addition of aggregated Aβ to neuron and astrocyte co-
cultures induced significant cell death, which was prevented by
TLR4 antagonists. Since it is not possible to perform reliable
immunohistochemistry on dead cells we used a method devel-
oped previously, based on measurement of the nuclei size of live
cells19, to determine if there was a change in the proportion of
surviving astrocytes and neurons in the co-culture, after treat-
ment. The astrocytes and neurons have nuclei size in distinct size
ranges with the neurons having smaller nuclei. Live cell imaging
(Supplementary Fig. 6a, b) suggested that neurons were more
Fig. 2 Response of BV2 microglial cells and astrocytes to soluble Abeta42 (Aβ) aggregates (oligomers) and the blocking of the TNF-α production by
TLR4 antagonists. a Time course of TNF-α production by BV2 cells in response to continual exposure to soluble Aβ oligomers (10 pM–1 nM) together with
monomer (monomer concentration 0.002–0.2 μM) (n= 4, sem). b The response of astrocytes to Aβ monomers, Aβ oligomers together with monomer
(oligomer concentration 0.25 to 1000 nM and total monomer concentration 0.05–200 μM) and Aβ fibrils (total monomer concentration) compared to LPS
(0.05–200 ng/ml) stimulation for 24 h (n= 4, mean ± sem). The astrocyte preparation had <2% microglial. c Time course of TNF-α production by
astrocyte cells in response to continual exposure to Aβ oligomers (10 pM–1 nM) together with monomer (total monomer concentration 0.002–0.2 μM)
(n= 4, mean ± sem). d The response of astrocytes after a 24 h incubation with Aβ oligomers (0.05–200 nM oligomer) together with monomer (total
monomer 0.01–40 μM)) only and together with the TLR4 antagonist RSLA (0.1 µg/ml), LPS and RSLA, RSLA only and the TLR4 antagonist TAK-242 (1 µM)
alone and with Aβ oligomers and monomer (n= 4, mean ± sem).
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vulnerable in the co-culture, since we observed a significant
increase in the average nuclei size of the surviving cells after
treatment (attributable to a greater proportion of surviving
astrocytes). We confirmed this result in an independent experi-
ment where we performed immunocytochemistry on the co-
culture, before and after addition of aggregated Aβ, and found
that the proportion of surviving astrocytes increased and the
proportion of neurons decreased (Supplementary Fig. 6c, d),
consistent with predominantly neuronal cell death. Our data
suggests that although both astrocytes and neurons exhibit
reduced viability on exposure to aggregated Abeta, the glial cells
are less vulnerable to cell death than the neurons. Overall our
experiments show that the main cause of neuronal cell death in
this acute dose experiment is caused by aggregate-initiated
TLR4 signalling by glial cells, astrocytes and the small fraction
of microglial present in the enriched astrocyte preparation. We
cannot work out the relative contribution of astrocytes and
microglia to this overall response, since although only 2% of the
glial are microglia, they have higher expression of TLR4.
Discussion
Here we have shown using rat neuron and glial cells that Aβ
aggregates cause LTP deficit and neuronal cell death pre-
dominantly by an autocrine/paracrine mechanism due to the
production of pro-inflammatory cytokines, predominantly by
TLR4 signalling by glial cells although we cannot rule out some
contribution from neurons in the LTP deficit experiment. These
experiments were performed with high doses of soluble aggre-
gates but we also showed that physiological doses of aggregates
over longer timespan also lead to the production of pro-
inflammatory cytokines due to a sensitized response, as
observed previously with alpha synuclein aggregates19. The con-
centration of TNF-α produced after several days approaches that
observed in the CSF of individuals with AD, 400 pg/ml20 and the
concentration produced by larger doses of aggregates in the LTP-
deficit experiments, 250 pg/ml.
There is a body of work that supports inflammation and
aggregation occur concurrently in the development of the
pathology of AD in both animal models and in humans, sug-
gesting positive feedback between aggregation and inflamma-
tion21. Furthermore, acute doses of aggregates can lead to
cognitive dysfunction22 mediated by the TNF receptor23 and
involving activation of P38 MAP kinase24. However, the rele-
vance of these observations to AD, which takes decades to
develop, and the mechanism by which cognitive dysfunction
occurs in AD has not been established. Our data suggests that
sensitized aggregate-induced inflammation over time leads to
LTP deficit and neuronal death, via TLR4 signalling, providing a
molecular basis for the memory loss observed in the progression
of AD, supported by the previous in vivo studies22,23. While our
experiments suggest that the TLR4 signalling is predominantly
from glial cells we cannot rule out a contribution from neurons
and in addition TLR4 expression has been shown to increase as
neurons age25, suggesting that the neuronal contribution may
increase with age in AD. Importantly our results point to an
autocrine/paracrine mechanism due to secreted pro-
inflammatory cytokines rather than direct binding of aggregates
to receptors on neurons. In terms of the relevance of our finding
to disease, we have recently found that the CSF from AD patients
is significantly more inflammatory than control CSF when
applied to BV2 cells over 5 days26. This shows that increased low
levels of inflammatory aggregates occurs with the development of
AD and in combination with the results in this paper that
aggregate-induced inflammation could contribute significantly to
the memory loss observed in these individuals. This inflammatory
response is mediated by Aβ containing aggregates in the CSF, via
TLR4 signalling, and correlates with the presence of protofibrils.
Our recent work also shows that synthetic Aβ aggregates exist in a
range of different size and structures with the longer protofibrils
being the inflammatory species11. Selectively targeting these
protofibrils rather than the fibrils, smaller aggregates or monomer
is challenging, so that blocking sensitized TLR4 signalling seems
an attractive alternative therapeutic strategy in AD. Memory loss
is an early symptom of AD and continues throughout the disease,
so this strategy could be used at all stages of disease and TLR4
antagonists could potentially be given intermittently, given the
nature of the priming response observed in this work.
Methods
Protein preparation. The Aβ was purchased from American peptide (Aβ 1–42,
1.0 mg). 1 mg of amyloid pure peptide was dissolved in 100% 1, 1, 1, 3, 3, 3-
Hexafluoro-2-propanol (HFIP) to a concentration of 2 mg/ml and incubated at
Fig. 3 Aβ42-mediated inhibition of LTP is rescued by RSLA but not TAK-
242 treatment. Top: Example traces of fEPSPs from indicated time-points.
Bottom: Mean fEPSP slope shown as percentage of the normalised baseline.
a The inhibition of LTP by application of oligomerised Aβ42 (5 nM
oligomers and 500 nM total monomer) was prevented by RSLA. b TAK-242
had no effect on Aβ-mediated inhibition of LTP. c TAK-242 and RSLA had
no effect on the expression of LTP compared with control. All symbols
represent the mean ± sem.
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room temperature until a clear solution was formed. The solution was then dried
under a nitrogen stream before dissolved once more in HFIP and sonicated. 100 μl
of solution was then aliquoted into an eppendorf and stored at −80 °C. When
required the solution was thawed and left open in a fume hood overnight to
evaporate the HFIP, leaving a peptide pellet. The peptide was dissolved in 10 μl of
100%DMSO and then transferred to a new eppendorf with DMEM.
Protein aggregation. Aβ oligomers were prepared by first diluting in DMEM
buffer (DMEM+ 1% FCS+ 2 mM L-glutamine). The aggregation mixture was
incubated for 6 h at 37 °C with constant shaking of 200 r.p.m (New Brunswick
Scientific Innova 43, 25 mm orbital diameter) and centrifuged for 10 min at 14,200
r.p.m. to remove any fibrillar pellets. Aβ fibrils were formed by aggregation for
60 h. Aggregated Aβ was then stored at 4 °C until incubated with cells. Using ThT
assays protein oligomers and fibrils were found to remain stable for 1 week after
removal from the shaking incubator however aggregates were always used
within 24 h.
ThT assay. The time course of the aggregation was monitored using thioflavin-T
(ThT) assays. ThT (Sigma-Aldrich) stocks were prepared in DMSO (Sigma-
Aldrich) and diluted into pre-filtered PBS (0.02 μm filter, Whatman) to a final
concentration of ~100 μM. Aβ was added to 1 ml of ThT solutions and binding
monitored by exciting the sample at 440 nm and recording the emission fluores-
cence spectrum from 460 to 560 nm (slit width 5 nm). Measurements were carried
out on a Cary Eclipse spectrofluorometer with a Peltier-controlled holder (Varian,
Mulgrave, Australia).
ThT imaging. ThT imaging utilised a method previously described27. Briefly glass
cover-slides (VWR international, 20 × 20 mm) were cleaned using an argon plasma
cleaner (PDC-002, Harrick Plasma) for at least 1 h to remove any residual that
fluoresce. 50 µL of poly-L-lysine (70,000–150,000 molecular weight, Sigma-Aldrich)
was added to the cover slides and incubated for 1 h before being gently washed with
filtered PBS. Imaging was performed on a custom-built total internal reflection
fluorescence microscope.
Cell culture. The BV2 cell lines were derived from immortalized murine neonatal
microglia. They were grown in Dulbecco’s modified Eagle’s (DMEM) supple-
mented with 10% foetal bovine serum and 1% L-glutamine (Life Technologies) and
incubated at 37 °C in a humidified atmosphere of 5% CO2 and 95% air, until
~1.6 × 106 cell/ml. Immortalized MyD88−/−, TLR2−/− and TLR4−/− murine cells
had previously been generated19 and grown from frozen stock samples under same
conditions as BV2. Astrocyte cells were from a rat mixed glial preparation, cultured
for 14 days with DMEM medium supplemented with 10% foetal bovine serum and
1% L-glutamine in a humidified atmosphere containing 5% CO2 at 37 °C. This
protocol minimizes the microglial contamination to <2%28. Astrocytes were cul-
tured to 70% confluence. For long duration experiments the media was exchanged
every 24 h.
ELISA assays. To determine cumulative TNF-α and Il-1β production, super-
natants were obtained after incubation with the Aβ over viable time frames and
stored at −80 °C until analysed. TNF-α, and Il-1β were analysed using the Duoset®
enzyme-linked immunosorbent assay (ELISA) development system (R&D Systems,
Abingdon, Oxfordshire, UK).
Animals. Electrophysiology experiments were conducted in accordance with the
UK Animals Scientific Procedures Act, 1986. Male Wistar rats (Charles River, UK)
were used to prepare acute hippocampal slices (4- to 5-week-old rats).
Electrophysiology. Brains were quickly removed into ice-cold artificial cere-
brospinal fluid (ACSF; 124 mM NaCl, 3 mM KCl, 26 mM NaHCO3, 1.25 mM
NaH2PO4, 2 mM CaCl2, 1 mM MgSO4, 10 mM D-glucose, carbogenated with 95%
O2/5% CO2). Transverse hippocampal slices (400 µm) were cut using a Mcllwain
tissue chopper (Mickle Laboratory Engineering) and allowed to recover in a
submersion-type bath filled with ACSF for at least 60 min. Before recording, hip-
pocampal slices were incubated in ACSF with pharmacological compounds at
room temperature. Evoked field excitatory postsynaptic potentials (fEPSPs) were
recorded in the CA1 region using glass electrodes containing NaCl (3 M). Twisted-
tungsten wire stimulating electrodes were positioned in the CA2 region (Schaffer
collateral pathway) and subiculum, and electric stimuli were delivered alternatively
to the two electrodes (0.066 Hz). After 30 min of stable baseline, high-frequency
tetanic stimulation (2 × 100 pulses; 100 Hz, 30 s interval) was used as the LTP
induction protocol. Long-term synaptic plasticity was gauged as the change of
fEPSP slope relative to the preconditioning baseline. Both control and experimental
recordings were collected using slices prepared from the same animal. Data were
captured and analysed using LTP114j software. Data are expressed relative to a
normalized baseline. For analyses, the baseline was defined as five time-points



























































































































































Fig. 4 Neuronal cell death caused by Aβ42 oligomers is mediated by initiating TLR4 signalling by glial cells. Cell death assay was performed using
Sytox green on a live-cell imaging platform. a TLR4 inhibitors (0.1 µg/ml RSA, 1 µM TAK242) did not prevent Aβ42 oligomer-induced cell death in pure
neuronal culture (5 nM oligomer and 1 µM total monomer). b, c Oligomer-induced astrocyte cell death was protected by TLR4 inhibitors. d, e Composition
of the co-culture assessed using MAP2 (neuronal marker) and GFAP (astrocytic marker) immunocytochemistry together with representative images of a
neuronal, astrocyte and co-culture. 97 ± 1.6% are MAP2-positive cells in neuronal prep, 92.2 ± 0.1% are GFAP-positive cells in astrocytic prep. 55.3 ± 7.1%
MAP2 (+) and 44.1 ± 1.3% GFAP (+) are found in co-culture prep. The proportion of CD11b-positive cells is 3.8 ± 0.4% and 1.3 ± 0.5% in the astrocytic and
co-culture preparations, respectively. (n= 5–6 from two independent experiments, mean ± sem).
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-0792-9 ARTICLE
COMMUNICATIONS BIOLOGY |            (2020) 3:79 | https://doi.org/10.1038/s42003-020-0792-9 | www.nature.com/commsbio 5
following recording commencement. The difference between baseline and post-
conditioning time-points was expressed as a percentage of baseline ± standard error
of the mean (SEM), and was used to make comparisons between treatment groups.
Statistical significance of observed effects between groups was analysed using
unpaired t-tests.
Aβ preparation for LTP experiments. The Aβ (1–42) peptide (Stratech, A-1163,
0.5 mg) was initially dissolved at a concentration of 1 mg/ml in 100% (HFIP
[Sigma-Aldrich]). This solution was incubated at room temperature for 1 h with
vortexing every 10 min. Next, the solution was sonicated for 10 min in a water bath
sonicator and then dried under a light stream of nitrogen gas. DMSO was added to
the peptide, which was incubated at room temperature for 10 min with gentle
mixing. Finally, this solution was aliquoted and stored at −80 °C. For a working
solution, D-PBS (Invitrogen, UK) was added to the peptide stock solution and
incubated for 2 h at room temperature for peptide oligomerisation. 500 nM oli-
gomerised amyloid-beta was applied to hippocampal slices in ACSF for 2 h. Pre-
vious experiments show this protocol results in a solution containing 1–5 nM
oligomers smaller than 10-mers15.
Rodent neuron and astrocyte culture. Cultures of cortical neurons and the co-
culture of neuron and astrocyte were prepared as described previously19. Briefly,
cortices of brain from either embryos (E16–17) or postnatal pups (day 2–4) of
Sprague-Dawley (UCL breeding colony) were collected for neuron and co-culture
preparations, respectively. The tissue was digested with EDTA–trypsin for 15 min
and washed before collecting pellets in complete neurobasal medium (Neurobasal
media supplemented with B27, 2 mM Glutamax and 50 I.U./ml Penicillin/50 μg/ml
Streptomycin). Approximately 50,000 cells for 96-well plates (Falcon/Corning Cat.
no.: 353219) and 100,000 cells for u-slide eight-well slide ibidi chamber (Thistle
Scientific Ltd, Cat. no.: IB-80826) were plated. Cells were used at 12–14 days
in vitro. Cortical astrocytes were purchased from Caltag Med Systems (Science Cell,
Cat. no.: R1800) which was derived from postnatal day 2 rat cortex. 7–10 times
sub-culture of cortical astrocytes were carried out until use. Cells were cultured in
rodent astrocyte medium (Caltag Medsystem, Cat. no.: 1831). All cells were
maintained in incubator at 37 °C (5% CO2).
Cell death assay. Cells were pre-treated with either 0.1 μg RSLA or 1 μM TAK-242
30 min prior to oligomer treatment. Cells were incubated with soluble aggregates
overnight and cell death was detected using Sytox green (Molecular Probes). Cells
were loaded with 0.5 μM Sytox green in HEPES balanced HBSS (pH adjusted at 7.4
with NaOH) for 15 min. High-throughput images were acquired using an Opera
Phenix High-Content Screening System (PerkinElmer). Sytox green staining was
imaged by 488 and 405 nm laser for Hoechst-stained nuclei (17–22 fields of images
were taken per wells). The percentage cell death was quantified by the ratio
between the number of Sytox green-positive cells and the total number of Hoechst-
expressing cells per image. The number of fluorescent cells was determined using
the multi-wavelength cell scoring module of Columbus Studio™ Cell Analysis
Software and each experiment utilised the same threshold settings (e.g. intensity
and size). Nuclei size of live cells (Sytox negative) was automatically acquired using
the same analysis software first in the neuron only culture, and the enriched
astrocyte culture. These size ranges were then used to determine the culture
composition of the co-culture before and after treatment with Abeta aggregates.
Immunohistochemistry. Cells were fixed in 4% paraformaldehyde and permea-
bilized with 0.2 Triton-X 100. Non-specific binding was blocked using 5% BSA.
Cells were incubated with primary antibodies for 1 h (MAP2; ab11267, GFAP;
ab4674, CD11b; ab133357) at room temperature and washed three times. Sec-
ondary antibodies (donkey anti rabbit 488; ab150073, donkey anti-mouse;
ab150110, goat anti-chicken 647; ab150171) were incubated for 1 h at room tem-
perature. Cells were washed three times and Hoechst was added in the second
wash. Cells were imaged with ProLong Diamond Antifade Mountant (Thermo
Fisher Scientific).
Statistics and reproducibility. For live cell imaging, there were total two inde-
pendent experiment which include different animals, different cell batch purchased
separately and cell preparation. Each set of independent experiments consists of
three wells per condition and the figures represent data polled from two inde-
pendent experiments. One-way ANOVA with Bonferroni or Tukey correction was
used to test statistical significance. One-way ANOVA with post hoc test was used
to test statistical significance in the production of TNF-α in the slice experiments.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Source data underlying Figs. 1 and 2 are in the Supplementary Data 1 file, Fig. 4a–c in
Supplementary Data 2 file and Supplementary Fig. 4d in Supplementary Data File 3. All
other data are available upon request from the corresponding author.
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